These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 18071953)

  • 21. The intracellular antibody capture technology: towards the high-throughput selection of functional intracellular antibodies for target validation.
    Visintin M; Quondam M; Cattaneo A
    Methods; 2004 Oct; 34(2):200-14. PubMed ID: 15312673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and selection of an intrabody library produced de-novo for the non-structural protein NSP5 of rotavirus.
    Vascotto F; Visintin M; Cattaneo A; Burrone OR
    J Immunol Methods; 2005 Jun; 301(1-2):31-40. PubMed ID: 15907924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Head-to-tail fusions of camelid antibodies can be expressed in planta and bind in rumen fluid.
    Winichayakul S; Pernthaner A; Scott R; Vlaming R; Roberts N
    Biotechnol Appl Biochem; 2009 Jun; 53(Pt 2):111-22. PubMed ID: 18844608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A universal strategy for stable intracellular antibodies.
    Shaki-Loewenstein S; Zfania R; Hyland S; Wels WS; Benhar I
    J Immunol Methods; 2005 Aug; 303(1-2):19-39. PubMed ID: 16045924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional inhibition of transitory proteins by intrabody-mediated retention in the endoplasmatic reticulum.
    Böldicke T; Somplatzki S; Sergeev G; Mueller PP
    Methods; 2012 Mar; 56(3):338-50. PubMed ID: 22037249
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intracellular antibodies as specific reagents for functional ablation: future therapeutic molecules.
    Lobato MN; Rabbitts TH
    Curr Mol Med; 2004 Aug; 4(5):519-28. PubMed ID: 15267223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monospecific bivalent scFv-SH: effects of linker length and location of an engineered cysteine on production, antigen binding activity and free SH accessibility.
    Albrecht H; Denardo GL; Denardo SJ
    J Immunol Methods; 2006 Mar; 310(1-2):100-16. PubMed ID: 16499921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intrabodies as drug discovery tools and therapeutics.
    Stocks M
    Curr Opin Chem Biol; 2005 Aug; 9(4):359-65. PubMed ID: 15979379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Domain antibodies: proteins for therapy.
    Holt LJ; Herring C; Jespers LS; Woolven BP; Tomlinson IM
    Trends Biotechnol; 2003 Nov; 21(11):484-90. PubMed ID: 14573361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional inactivation of the conserved Sem1p in yeast by intrabodies.
    Reinman M; Jäntti J; Alfthan K; Keränen S; Söderlund H; Takkinen K
    Yeast; 2003 Sep; 20(12):1071-84. PubMed ID: 12961755
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering antibodies for stability and efficient folding.
    Honegger A
    Handb Exp Pharmacol; 2008; (181):47-68. PubMed ID: 18071941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment.
    Magdelaine-Beuzelin C; Kaas Q; Wehbi V; Ohresser M; Jefferis R; Lefranc MP; Watier H
    Crit Rev Oncol Hematol; 2007 Dec; 64(3):210-25. PubMed ID: 17624800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies.
    Rothe C; Urlinger S; Löhning C; Prassler J; Stark Y; Jäger U; Hubner B; Bardroff M; Pradel I; Boss M; Bittlingmaier R; Bataa T; Frisch C; Brocks B; Honegger A; Urban M
    J Mol Biol; 2008 Feb; 376(4):1182-200. PubMed ID: 18191144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intrabodies as therapeutic agents.
    Kontermann RE
    Methods; 2004 Oct; 34(2):163-70. PubMed ID: 15312669
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intracellular antibodies and challenges facing their use as therapeutic agents.
    Lobato MN; Rabbitts TH
    Trends Mol Med; 2003 Sep; 9(9):390-6. PubMed ID: 13129705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific in vivo knockdown of protein function by intrabodies.
    Marschall AL; Dübel S; Böldicke T
    MAbs; 2015; 7(6):1010-35. PubMed ID: 26252565
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A therapeutic Trojan horse: intracellular antibodies].
    Teillaud JL
    Pathol Biol (Paris); 1999 Oct; 47(8):771-5. PubMed ID: 10573694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a stable recombinant antibodies repertoire for the direct selection of functional intracellular reagents.
    Villani ME; Di Carli M; Donini M; Traversini G; Lico C; Franconi R; Benvenuto E; Desiderio A
    J Immunol Methods; 2008 Jan; 329(1-2):11-20. PubMed ID: 17980894
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selection and characterization of KDEL-specific VHH antibody fragments and their application in the study of ER resident protein expression.
    Klooster R; Eman MR; le Duc Q; Verheesen P; Verrips CT; Roovers RC; Post JA
    J Immunol Methods; 2009 Mar; 342(1-2):1-12. PubMed ID: 19041652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains.
    Narayanan A; Sellers BD; Jacobson MP
    J Mol Biol; 2009 May; 388(5):941-53. PubMed ID: 19324053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.